In support of improving patient care, this activity has been planned and implemented by the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) and Harborside Medical Education. The Annenberg Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Continuing Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Annenberg Center designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center designates this live activity for a maximum of 13.0 ANCC contact hours.
The Annenberg Center designates this live activity for a maximum of 13.0 contact hours (0.130 CEUs) of continuing pharmacy credit. Credit will be provided to the NABP CPE Monitor within 60 days after the activity completion.
The Annenberg Center for Health Sciences at Eisenhower has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Continuing Education Credit
To be eligible for documentation of credit, participants must attend the full activity and submit a completed evaluation form. Participants must complete the evaluation online by December 31, 2023.
Upon completion of this activity, participants should be better able to:
- Identify treatment procedures for patients with select solid tumors and hematologic malignancies, based on recent FDA approvals and practice guideline updates
- Assess the clinical relevance of efficacy and safety data from recently published studies of cancer therapies
- Recognize and manage adverse events (AEs) associated with newer systemic therapies, and
- Apply collaborative approaches to enhance communication with, and the quality of life of, patients undergoing treatment for cancer
The intended audience for this live conference is nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, hematology/oncology nurses, pharmacists, and clinicians who specialize in the field of oncology.
Amy Pierre, MSN, ANP-C
Memorial Sloan Kettering Cancer Center and Flatiron Health
Jason Astrin, DMSc, MBA, PA-C, DFAAPA
The US Oncology Network
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP®
North Carolina Cancer Hospital
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
Carolyn Grande, CRNP, AOCNP®
Abramson Cancer Center
Andy Guinigundo, MSN, RN, CNP, ANP-BC
Cincinnati Cancer Advisors
Lisa Hwa, APRN, DNP, CNP
Lisa Kottschade, APRN, MSN, CNP
Heather Lewin, MSN, APRN
Nancy Nix, PharmD, BCPS, BCOP
Kristen O’Hagen, ANP, AOCNP®
Memorial Sloan Kettering Cancer Center
Beth Sandy, MSN, CRNP
Abramson Cancer Center
Kate Taucher, PharmD, MHA, BCOP, FAPO
UCHealth Memorial Hospital
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals with the potential to impact the content of an accredited education activity are expected to identify and reference off-label product use and disclose relevant financial relationships with ACCME-defined ineligible companies.
The Annenberg Center for Health Sciences assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant financial relationships that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Jason Astrin has no relevant financial relationships to disclose.
Lorinda Coombs has no relevant financial relationships to disclose.
Beth Faiman is a consultant for Amgen, BMS, Janssen and Pfizer.
Carolyn Grande has no relevant financial relationships to disclose.
Andy Guinigundo is a consultant for Amgen, and Jazz Pharma; is on the Speaker’s Bureau for Amgen, Astellas, GSK, and Pfizer.
Lisa Hwa is on the Advisory Board for Akcea, GSK and Sanofi.
Lisa Kottschade is a consultant for Immunocore and Novartis.
Sandy Kurtin is a consultant for Abbvie, Amgen, AstraZeneca, BMS and Incyte.
Heather Lewin owns stock in Roche.
Nancy Nix is a Speaker for AstraZeneca, Coherus and Pfizer.
Kristen O’Hagan has no relevant financial relationships to disclose.
Amy Pierre is on the Advisory Board for Janssen and Pfizer and is an educational speaker for BMS.
Beth Sandy is an Advisor for Janssen, a Speaker for Amgen, AstraZeneca, Jazz, Lilly, Merck and Takeda.
Kate Taucher has no relevant financial relationships to disclose.
All other staff at the Annenberg Center and Harborside Medical Education have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals as well as those disclosed during the course of the activity have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.